Gerresheimer ramps up glass and plastic production capacities in India

By Jane Byrne

- Last updated on GMT

© GettyImages/PeopleImages
© GettyImages/PeopleImages

Related tags Glass packaging Gerresheimer Syringe prefillable Plastic

Gerresheimer has enhanced its manufacturing capabilities in India, in an effort to ensure consistent, local supply for pharma and healthcare operations.

The packaging group has opened a new plant producing plastic containers and closures at its Kosamba manufacturing site.

It has also invested “a double digit million Euro amount”​ in new furnaces at its molded glass plant at that location, installing a Type I Borosilicate melting furnace for flint and amber glass production using cross-fired oxygen technology and an increased portion of electric heating to melt its Barium free type I glass formulation.

With this technology, we will substantially enhance our product quality and address additional market segments,”​ said Stefan Rieder, global senior vice president commercial molded glass, Gerresheimer.

The company now has four facilities in India, focused on pharmaceutical primary packaging made of plastic, molded and tubular glass. 

Boosting production capacity in India is part of Gerresheimer’s emerging markets growth strategy execution plans; it is addressing what it sees as the global mega trend for increasing health care access in these markets and the rising demand for vaccination. 

“India is one of the strongest growing emerging markets and a core market for large global pharma companies​” said Gerresheimer CEO, Dietmar Siemssen.

With plants in Europe, North and South America and Asia, the packaging firm generates annual sales of around €1.4bn. Its range includes pharmaceutical packaging and products from insulin pens, inhalers, micropumps, prefillable syringes, injection vials, ampoules, bottles, and containers for liquid and solid medications with closure and safety systems, along with cosmetics packaging.

Revenue growth on track

The company announced last month that it had delivered double-digit growth in both revenue and adjusted EBITDA in its first quarter 2022, with it increasing its revenue guidance for the full financial year.

Revenue in its plastics and devices division in Q1 came to €186m (US$193.9m), up from €155.3m in same quarter in 2021, it reported.

“Demand for plastic packaging and syringes was particularly high, while [the] contract manufacturing business also developed positively. Plastic packaging revenues additionally benefited from price increases resulting from higher resin prices being passed onto customers.”​ 

Related news

Show more

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers